Navigation Links
Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 Second Quarter Financial Results
Date:7/28/2009

THE WOODLANDS, Texas, July 28 /PRNewswire-FirstCall/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, today updated its drug development progress and reported financial results for the three months and six months ended June 30, 2009.

"Our clinical development programs continue to progress, including the recent initiation of a Phase 2 study of LX1032 in patients with carcinoid syndrome," said Dr. Arthur T. Sands, president and chief executive officer of Lexicon. "We also expect to advance LX2931 for rheumatoid arthritis into a Phase 2 clinical trial in the very near future."

Key Developments

  • Lexicon advanced its LX1032 drug candidate, which has received Fast Track status from the U.S. Food and Drug Administration (FDA), into a Phase 2a study in patients with carcinoid syndrome. The Phase 2 clinical trial is designed as a randomized, double-blind, placebo-controlled study to evaluate the safety and tolerability of LX1032 and its effects on symptoms associated with carcinoid syndrome. The study will include up to 28 patients with carcinoid syndrome who are symptomatic despite treatment with currently available therapy. In addition, Lexicon presented Phase 1 data for LX1032 at the Digestive Disease Week (DDW) annual meeting on June 1, 2009. Most recently, Lexicon received orphan drug designation for L
    '/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine news :

1. Raptor Pharmaceuticals Corp. and TorreyPines Therapeutics, Inc. Announce Merger Agreement
2. Millennium Pharmaceuticals Inc./Lymphoma Research Foundation funds lymphoma research
3. Quark Pharmaceuticals Announces Data Indicating Potential Utility of QPI-1007 for Treatment of Glaucoma
4. Access Pharmaceuticals Announces Commercial Launch of MuGard(TM) in Norway by SpePharm
5. Sunesis Pharmaceuticals Appoints Helen S. Kim to Board of Directors
6. Hisamitsu Pharmaceutical Co., Inc. Begins Tender Offer for All Outstanding Shares of Noven Pharmaceuticals, Inc.
7. Webcast Alert: Isis Pharmaceuticals Second Quarter 2009 Financial Results Conference Call
8. UPDATE: Access Pharmaceuticals to Present at Jesup & Lamont 2009 Growth Stock Conference
9. Access Pharmaceuticals to Present at Jesup & Lamont 2009 Growth Stock Conference
10. Transcept Pharmaceuticals to Present at BMO Capital Markets Healthcare Conference on August 5, 2009
11. EPIX Pharmaceuticals, Inc. Assigns all Its Assets to Joseph F. Finn, Jr., C.P.A. for the Benefit of Its Creditors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... Angelo’s FabriClean has recently announced that ... clients that avail the area rug cleaning services. Area ... with hi-tech equipments, making use of the quick drying ... natural, high pressure steam extraction to clean even the ... area rugs made with delicate fabric. , “Good ...
(Date:4/21/2015)... April 21, 2015 Catalent (Booth ... technologies and development solutions for drugs, biologics and ... ADVASEPT™ Lock, a stopper-less, glass- and needle-free vial ... medications. Easily opened, ADVASEPT Lock attaches to a ... container closure with the security of an advanced ...
(Date:4/21/2015)... QuickMedical, a veteran-owned leader in ... represents Schiller America's line of Ambulatory ... and Vital Signs Monitors, among many other items. ... global leader in the development and production of ... close cooperation with the world's leading physicians and ...
(Date:4/21/2015)... (PRWEB) April 21, 2015 The ... Citrate Industry is a professional and in-depth study ... Sodium Citrate Market with a focus on ... in the sodium citrate market research are Cargill, ... Natural Biological, Cofco Biochemical, Capchem, Lianyungang Mupro Fi, ...
(Date:4/21/2015)... April 21, 2015 Further strengthening ties ... $1.2 million in donated goods and services to the ... through the USF Health BRIDGE Healthcare Clinic. , The ... clinic in its eighth year – provides primary medical ... one night a week inside the USF Health Morsani ...
Breaking Medicine News(10 mins):Health News:Angelo’s FabriClean Now Offers Area Rug Cleaning in South Surrey with Complimentary Pick-Up and Delivery 2Health News:Catalent Announces the Expansion of its Advanced, Aseptic, Glass-Free Injectable Platform with New ADVASEPT™ Lock Delivery Technology 2Health News:QuickMedical Launches New Product Line: Schiller America 2Health News:QuickMedical Launches New Product Line: Schiller America 3Health News:Sodium Citrate Industry Global Key Manufacturers Analysis Report 2015-2020 2Health News:Sodium Citrate Industry Global Key Manufacturers Analysis Report 2015-2020 3Health News:USF Health and Florida Hospital Tampa Partner to Expand BRIDGE Clinic 2Health News:USF Health and Florida Hospital Tampa Partner to Expand BRIDGE Clinic 3
... 24, 2011David Satcher, MD, PhD, former U.S. Surgeon General, describes ... and adult health that we are facing today," calling for ... in the June issue of Childhood Obesity , a ... is available online. A long-time advocate in the ...
... , FRIDAY, June 24 (HealthDay News) -- Drinking even ... concentrations enough to increase the chances of being seriously injured ... get behind the wheel, a new study suggests. Researchers ... a blood-alcohol concentration of just 0.01 percent -- much lower ...
... June 24, 2011 A new anti-inflammatory drug used by ... a year-long study involving researchers from UT Southwestern Medical Center. ... Journal of Medicine , mark the first time a drug ... type 2 diabetes and chronic kidney disease. Previous studies have ...
... Researchers from Boston University,s Slone Epidemiology Center have found ... (MHC) that confer a higher risk of systemic lupus ... currently appears on-line in Human Genetics , is ... association between genetic variants in the MHC region and ...
... , THURSDAY, June 23 (HealthDay News) -- After suffering a ... and fears about the future are less depressed and live ... In fact, 48 percent of the people who participated in ... were not depressed a year later, compared to 37.7 of ...
... (HealthDay News) -- New research suggests that the adverse effects ... latest findings, from a University of Rhode Island study that ... revealed that preemies grow up to be less healthy, struggle ... compared to those born full-term. One reason for this, ...
Cached Medicine News:Health News:Even One Glass of Beer, Wine Boosts Car Crash Risk: Study 2Health News:Drug shows improved kidney function for type 2 diabetics, UT Southwestern researchers report 2Health News:New genetic risk factors of lupus found in study of African-American women 2Health News:Early Talk Therapy May Help Stroke Patients Bounce Back 2Health News:Early Talk Therapy May Help Stroke Patients Bounce Back 3Health News:Effects of Premature Birth May Stretch Into Adulthood: Study 2
(Date:4/21/2015)... , April 21, 2015 Cardiologists at Henry ... of stroke in patients with an irregular heartbeat. ... procedure, Henry Ford is able to add another ... atrial fibrillation, which affects the heart,s ability to pump. ... and first-ever commercial Watchman implant at a non-clinical ...
(Date:4/21/2015)... 21, 2015  Celebrating a major anniversary and ... same time is fitting for Enova Illumination. In ... surgical headlights, LED technology was a new concept ... been at the forefront of LED surgical headlight ... lightest and most dependable LED surgical headlights available. ...
(Date:4/21/2015)... , April 21, 2015 Workers, compensation ... 5.4 percent decrease in utilization helped offset a 7 ... new data released today by Express Scripts (NASDAQ: ... Workers, Compensation Drug Trend Report discusses the overall pharmacy ... among injured workers. Opioid Management Mitigates ...
Breaking Medicine Technology:Stroke Risk Caused by Abnormal Heart Rhythm Reduced Without Blood Thinners 2Stroke Risk Caused by Abnormal Heart Rhythm Reduced Without Blood Thinners 3Enova Illumination Celebrates 10th Anniversary at Cutting Edge of LED Surgical Headlight Innovation; Introduces Newest and Brightest LED Surgical Headlight in the World 2Enova Illumination Celebrates 10th Anniversary at Cutting Edge of LED Surgical Headlight Innovation; Introduces Newest and Brightest LED Surgical Headlight in the World 3Workers' Compensation Prescription Drug Spend Increased 1.9 Percent in 2014, Stabilized by Effective Utilization Management Programs 2Workers' Compensation Prescription Drug Spend Increased 1.9 Percent in 2014, Stabilized by Effective Utilization Management Programs 3Workers' Compensation Prescription Drug Spend Increased 1.9 Percent in 2014, Stabilized by Effective Utilization Management Programs 4
... WAYNE, N.J., June 6, 2011 Bayer HealthCare Pharmaceuticals ... AL pharadin in SYM ptomatic P rostate ... chloride, which is exclusively licensed from Algeta ASA, in ... met its primary endpoint by significantly improving overall survival. ...
... June 5, 2011 Nektar Therapeutics (Nasdaq: ... of patients in a Phase 2 clinical study evaluating ... total of 33 women in the study with prior ... for response rate using either RECIST 1.0 criteria (response ...
Cached Medicine Technology:Bayer's Investigational Compound Radium-223 Chloride Met its Primary Endpoint of Significantly Improving Overall Survival in a Phase III Trial in Patients with Castration-Resistant Prostate Cancer That Has Spread to the Bone 2Bayer's Investigational Compound Radium-223 Chloride Met its Primary Endpoint of Significantly Improving Overall Survival in a Phase III Trial in Patients with Castration-Resistant Prostate Cancer That Has Spread to the Bone 3NKTR-102 Shows High Response Rate and Sustained Duration of Response in Women with Platinum-Resistant/Refractory Ovarian Cancer Previously Treated with Doxil® 2NKTR-102 Shows High Response Rate and Sustained Duration of Response in Women with Platinum-Resistant/Refractory Ovarian Cancer Previously Treated with Doxil® 3NKTR-102 Shows High Response Rate and Sustained Duration of Response in Women with Platinum-Resistant/Refractory Ovarian Cancer Previously Treated with Doxil® 4NKTR-102 Shows High Response Rate and Sustained Duration of Response in Women with Platinum-Resistant/Refractory Ovarian Cancer Previously Treated with Doxil® 5NKTR-102 Shows High Response Rate and Sustained Duration of Response in Women with Platinum-Resistant/Refractory Ovarian Cancer Previously Treated with Doxil® 6NKTR-102 Shows High Response Rate and Sustained Duration of Response in Women with Platinum-Resistant/Refractory Ovarian Cancer Previously Treated with Doxil® 7NKTR-102 Shows High Response Rate and Sustained Duration of Response in Women with Platinum-Resistant/Refractory Ovarian Cancer Previously Treated with Doxil® 8
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: